This site is intended for healthcare professionals

EU approves Xevudy for COVID-19.- GSK + Vir Biotechnology

Read time: 1 mins
Last updated:20th Dec 2021
Published:18th Dec 2021
GlaxoSmithKline and Vir Biotechnology announced that the European Commission has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19.

Sotrovimab is now approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. The grant of the marketing authorization in the EU is a result of the positive opinion issued on December 16 by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

The grant of the marketing authorization in the EU is based on data from the COMET-ICE Phase III trial, demonstrating that intravenous treatment with sotrovimab resulted in a 79% reduction (adjusted relative risk reduction) (p<0.001) in all-cause hospitalizations for more than 24 hours or death due to any cause by day 29 compared to placebo, meeting the primary endpoint of the trial. in absolute numbers, 30 (6%) of the 529 patients in the placebo arm progressed, compared to six (1%) of the 528 patients receiving sotrovimab. in clinical trials conducted to date, sotrovimab has been well-tolerated. the most common adverse reactions are hypersensitivity and infusion-related reactions, seen in approximately 2% and 1% of cases, respectively.></0.001)>

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.